Elevated plasma levels of plasminogen activator inhibitor-1 are associated with risk of future incident venous thromboembolism.

ABSTRACT:

Background

Plasminogen activator inhibitor-1 (PAI-1), the main inhibitor of fibrinolysis, is frequently elevated in obesity and could potentially mediate the risk of venous thromboembolism (VTE) in obese subjects. However, whether PAI-1 is associated with VTE remains uncertain.

Objective

To investigate the association between plasma PAI-1 levels and risk of future incident VTE and whether PAI-1 could mediate the VTE risk in obesity.

Methods

A population-based nested case-control study, comprising 383 VTE cases and 782 age- and sex-matched controls, was derived from the Tromsø Study cohort. PAI-1 antigen levels were measured in samples collected at cohort inclusion. Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs) for VTE

SUBMITTER: Frischmuth T 

PROVIDER: S-EPMC9314992 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature